Upload
reddygaari-abbayi
View
229
Download
0
Embed Size (px)
Citation preview
8/13/2019 Amino Glyc o Sides 4444
1/25
A SEMINAR
ON
AMINOGLYCOSIDES-ANTIBIOTICSA REVIEW WORK
Submitted to Jawaharlal Nehru Technological University, Hyderabad
In partial fulfillment for the award of the degree of
BACHELOR OF PHARMACY
By
M.SANTHOSH KUMAR
(10T21R0058)
Under the Guidance of
DR.T.RAMA MOHAN REDDY. M.Pharm, PH.D
Dept. Of MEDICINAL CHEMISTRY
(Approved by AICTE & PCI, Affiliated to JNTU, Hyderabad)
Kandlakoya (V), Medchal Road, Hyderabad -501401.
8/13/2019 Amino Glyc o Sides 4444
2/25
CMR COLLEGE OF PHARMACY
(Approved by AICTE and PCI)
(Affiliated to JNTUH)
CERTIFICATE
This is to certify that the seminar described in this review entitled
AMINOGLYCOSIDES-ANTIBIOTICSis submitted to JNTU, Hyderabad in
partial fulfillment of award of the Bachelor of Pharmacy. It is also certified that the
work was carried out by, M.SANTHOSH KUMAR (10T21R0058)CMRCollege of Pharmacy, kandlakoya, Medchal Road, Hyderabad under my guidance
and supervision during the academic year 2013-2014.
PRINCIPAL GUIDE
V. Uma maheshwar rao M.pharm, Ph.D. DR.T.RAMA MOHAN REDDY.M.Pharm, PH.D
8/13/2019 Amino Glyc o Sides 4444
3/25
CMR COLLEGE OF PHARMACY(Approved by AICTE and PCI)
(Affiliated to JNTUH)
DECLARATION
I hereby declare that the seminar entitled AMINOGLYCOSIDES-
ANTIBIOTICS is carried out by me under the guidance of DR.T.RAMA
MOHAN REDDY. M.Pharm, PH.D,Associate professor.
M.SANTHOSH KUMAR(10T21R0058)
8/13/2019 Amino Glyc o Sides 4444
4/25
AMINOGLYCOSIDES-ANTI BIOTICS
An aminoglycosideis a molecule or a portion of a molecule composed of amino-
modified sugars
The aminoglycoside antibiotics constitute an important category of antibacterial agents in the
Therapeutic armamentarium, e.g., streptomycins, neomycins, paramomycins, kanamycins,gentamycinsand the corresponding derivatives of these antibiotics.
These are a bunch of closely related chemically basic carbohydrates that are mostly water-
soluble.Their respective hydrochlorides and sulphates are crystalline in nature. They are found to be
effective in
inhibiting the growth of gram-positive as well as gram-negative bacteria. They are also effective
to a great extent against mycobacteria.
Group of antibiotics used in the treatment of bacterial infections aerobic G-ve Consists of 2 or more amino sugars and a hexose nucleus Serious toxicity is a limiting factor for their application Streptomycinwas the first to be discovered in 1943 by Schatz, Bugie and Waksman
Families:
Determined by the type of amino sugar Neomycin there are 3 amino sugars attached to 2-deoxystreptamine e.g Neo B,
Paromomycin
Kanamycin family 2 amino sugars attached to 2 deoxystreptamine. E.gs amikacin.Kanamycin A & B, tobramycin
a semisynthetic derivative of kanamycin A and netilmicin is also semisyntheticAminoglycosides family
Gentamicin family- Gent Ci, Gent C1a and C2,
8/13/2019 Amino Glyc o Sides 4444
5/25
sisomicin Streptomycin family
Streptomycin and Dihydrostreptomycin. Contains streptidine instead of deoxystreptamine
Other examples are
Gentamicin* Streptomycin Amikacin Neomycin Netilmicin* Tobramycin Kanamycin Paromomycin+
Spectrum of activity Aerobic G-ve bacteria Citrobacter, Enterobacter, E. coli, proteus, Pseudomonas,
Enterococci and Staph aureus.
Lack activity against most anaerobic or facultative bacteria and activity against G+veorganisms is limited
Mechanism of Action
Bactericidal antibiotics Penetration involves active transport Inhibition of protein synthesis by binding to the 30S subunit of ribosomes Causes misreading and premature termination of protein synthesis
8/13/2019 Amino Glyc o Sides 4444
6/25
Resistance
May be plasmid mediated inactivation by microbial enzymes or failure of drugpenetration
Synthesis of metabolizing enzymes Mutation may alter ribosomal binding site for the aminoglycosides Cross resistance with other aminoglycosides may occur
Absorption, Distribution and Elimination
Polar agents with poor oral absorption Usual routes: IM or I.V Cmax achieved within 30-90 of IM Absorption increases in inflammation No significant amount in breast milk Plasma protein binding is minimal Vd approximates 25% of lean body weight Penetration of CNS: 10-25% of plasma level Accumulates in the perilymph and endolymph as well as renal cortex Vd increases inleukaemia Clearance increases and T1/2 reduces in cystic fibrosis T1/2 for most; 2-3 hours Elimination is by glomerular filtration Both haemo- and peritoneal dialysis remove aminoglycosides
Therapeutic drug monitoring
Necessary in:
Patients with life threatening infections Renal impairment
8/13/2019 Amino Glyc o Sides 4444
7/25
24 hours into new regimen Neonates Samples usually taken just before and 30 minutes after a dose
Caution in:
Pregnancy Myasthenia gravis (MG) Renal impairment Parkinsons dx 8thcranial nerve disease
In general, they are prepared biosynthetically exclusively from an admixture of carbohydratecomponents of the fermentation media.
They usually act by causing interference with the reading of the genetic code.
A few typical examples cited earlier shall be discussed below:
STREPTOMYCIN
Usual dosage: 15-25 mg per Kg body wt IMTherapeutic applications in:
Bacterial endocarditis from enterococcal and group D Strep Tularemia Plague Tuberculosis
8/13/2019 Amino Glyc o Sides 4444
8/25
Streptomycin is chiefly employed in the treatment of tuberculosis in conjunction with other
drugs such as isoniazid and rifampicin.
Streptomycin and penicillin exert a synergistic action against bacteria and are usually employed
together in the treatment of subacute bacterial endocarditis caused byStreptococcus faecalis
It exerts bacteriostatic action in low concentrations and bactericidal in high concentrationsagainst a plethora of Gram-negative and Gram-positive organisms.
The only infection wherein this drug alone is the drug of choice aretularemia and bubonicplague. A combination with a tetracycline it may be employed in the treatment of brucellosis and
infections produced by Pseudomonas mallei. It is also an alternative drug of choice in the
treatment of chancroid, rat-bite fever and tuberculosis.
Streptomycin INN, Streptomycin Sulphate BAN, Streptomycin Sulfate USAN,
8/13/2019 Amino Glyc o Sides 4444
9/25
STREPTOMYCIN
5-(2,4-diguanidino-3,5,6-trihydroxy-cyclohexoxy)- 4-[4,5-dihydroxy-6-(hydroxymethyl)
-3-methylamino-tetrahydropyran-2-yl] oxy-3-hydroxy-2-methyl
-tetrahydrofuran-3-carbaldehyde
Dose.
For non-tuberculosis infections, usual, 1g per day up to 5 to 10 days.
Mechanism of Action.
The drug exerts its maximum effectiveness against the organism Mycobacteriumtuberculosis. Interestingly, the antibiotic is not a cure itself but has proved to be anexcellent and valuable adjunct to other modalities of therapeutic treatment for
tuberculosis.
It acquires a rapid development with respect to certain strains of microorganisms. The combined administration of streptomycin and penicillinhas been suggested to combat
infections which may be due to organisms that are sensitive to both these antibiotics.
The drug is neither absorbed nor destroyed appreciably in the GI tract.
8/13/2019 Amino Glyc o Sides 4444
10/25
SAR of Streptomycin.
The drug serves as a triacidic basedue to the presence of two characteristic chemicalentities, namely:
(a) two strongly basic guanido moieties.
(b) rather weakly basic methylamino function.
Furthermore, hydroxy-streptomycin differs from streptomycin in essentially having astrategically positioned OH moiety in place of one of the H-atoms of the streptose methyl
function.
Besides, streptomycin B (i.e., mannisido streptomycin) possesses a mannoseresidueattached to a glycosidic linkage via a OH moiety at C-4 of the N-methyl-L-
glucosamine functional group. The designated stereo chemical structure of the drug hasbeen reconfirmed via the total synthesis.
Treatment of diseases
Infective endocarditis caused by enterococcus when the organism is not sensitivetoGentamicin
Tuberculosis in combination with other anti-TB drugs. It is not the first-line treatment,except in medically under-served populations where the cost of more expensive
treatments is prohibitive.
Plague (Yersinia pestis)has historically been treated with it as the first-line treatment. Itis approved for this purpose by theU.S. Food and Drug Administration.
Inveterinary medicine, streptomycin is the first-line antibiotic for use againstgramnegativebacteria in large animals (horses,cattle,sheep,etc.). It is commonly combined
with procainepenicillin for intramuscular injection.
Side Effects of Use
Fever and rashes result from persistent use. The Vestibular portion of cranial nerve VIII (the vestibulococlear nerve) can be
affected, resulting intinitus,vertigo andataxia.
It can also lead tonephrotoxicity.
http://en.wikipedia.org/wiki/Infective_endocarditishttp://en.wikipedia.org/wiki/Gentamicinhttp://en.wikipedia.org/wiki/Tuberculosishttp://en.wikipedia.org/wiki/Plague_(disease)http://en.wikipedia.org/wiki/Yersinia_pestishttp://en.wikipedia.org/wiki/U.S._Food_and_Drug_Administrationhttp://en.wikipedia.org/wiki/Veterinary_medicinehttp://en.wikipedia.org/wiki/Gram_negativehttp://en.wikipedia.org/wiki/Gram_negativehttp://en.wikipedia.org/wiki/Horseshttp://en.wikipedia.org/wiki/Cattlehttp://en.wikipedia.org/wiki/Sheephttp://en.wikipedia.org/wiki/Penicillinhttp://en.wikipedia.org/wiki/Tinitushttp://en.wikipedia.org/wiki/Vertigohttp://en.wikipedia.org/wiki/Ataxiahttp://en.wikipedia.org/wiki/Nephrotoxicityhttp://en.wikipedia.org/wiki/Nephrotoxicityhttp://en.wikipedia.org/wiki/Ataxiahttp://en.wikipedia.org/wiki/Vertigohttp://en.wikipedia.org/wiki/Tinitushttp://en.wikipedia.org/wiki/Penicillinhttp://en.wikipedia.org/wiki/Sheephttp://en.wikipedia.org/wiki/Cattlehttp://en.wikipedia.org/wiki/Horseshttp://en.wikipedia.org/wiki/Gram_negativehttp://en.wikipedia.org/wiki/Gram_negativehttp://en.wikipedia.org/wiki/Veterinary_medicinehttp://en.wikipedia.org/wiki/U.S._Food_and_Drug_Administrationhttp://en.wikipedia.org/wiki/Yersinia_pestishttp://en.wikipedia.org/wiki/Plague_(disease)http://en.wikipedia.org/wiki/Tuberculosishttp://en.wikipedia.org/wiki/Gentamicinhttp://en.wikipedia.org/wiki/Infective_endocarditis8/13/2019 Amino Glyc o Sides 4444
11/25
NEOMYCIN
Neomycin is mostly used in a wide variety of local infection such as burns, ulcers,wounds,
Impetigo, infected dermatoses, furunculosis, conjunctivitis, etc. It is also employed as an adjuvant intopical steroid preparations to control secondary
infections in the case of inflammatory disorders.
The drug is employed to produce intestinal antisepsis prior to large bowel surgery, forthetreatment of gastroenteritis produced by toxigenic E. coli, and also to affordsuppression of ammoniaproducing bowel flora in the management of hepatic coma.
As it causes a rapid overgrowth of nonsusceptible organism, including staphylococci, oraltherapy must not be prolonged in any case formore than 3 days.
It displays broad-spectrum activity against a good number of pathogenic organisms. Besides, it demostrates a low incidence of toxic and hypersensitivity reactions.
Neomycin INN, Neomycin Sulphate BAN, Neomycin Sulphate USAN,
8/13/2019 Amino Glyc o Sides 4444
12/25
NEOMYCIN
2S,3S,4S,5R)-5-amino-2-(aminomethyl)-6-((2R,3S,4R,5S)-5-((1R,2R,5R,6R)-3,5-diamino-2-
((2R,3S,4R,5S)-3-amino-6-(aminomethyl)-4,5-dihydroxytetrahydro-2H-pyran-2-yloxy)-6-
hydroxycyclohexyloxy)-4-hydroxy-2-(hydroxymethyl)tetrahydrofuran-3-yloxy)tetrahydro-2H-pyran-3,4-diol
Dose:
Topical, to the skin, as 5% solution, aerosol or ointment 2 to 3 times a day.
Mechanism of Action.
The drug usually gets absorbed very rarely from the digestive system;Therefore, its oral administration primarily fails to produce any substantial systemic effect.
SAR of Neomycin.
The structures of neomycin A (neamine), neomycin B and neomycin C have beenestablished besides, the absolute configurational structures of neomycin and neamine
have been reported.
8/13/2019 Amino Glyc o Sides 4444
13/25
It has been demonstrated that neamine could be obtained by the methanolysis ofneomycin B and C respectively, whereby the glycosidic linkage existing between D-
ribose and deoxystreptamine undergoes cessation.
Spectrum
Similar to other aminoglycosides, neomycin has excellent activity againstGram-negative bacteria,and has partial activity againstGram-positive bacteria.
It is relatively toxic to humans, and many people have allergic reactions toit.Hypersensitivity. Physicians sometimes recommend using antibiotic ointments
without neomycin, such asPolysporin.
History
Neomycin was discovered in 1949 by the microbiologistSelman Waksmanand hisstudent Hubert Lechevalier at Rutgers University.
It is produced naturally by the bacteriumStreptomyces fradiae.Neomycin as a DNA binder
Neomycin belongs to the family of aminoglycosides. Aminoglycosides are known for their ability to bind to duplex RNA with high affinity. A study done by Daniel Pilch, Associate Professor Dept. of Pharmacology at Rutgers
University, and his coworkers determined the association constant for neomycin with A-site RNA was found to be in the ~10
9M
-1range.
However, more than 50 years after its discovery, its DNA-binding properties were stillunknown. In 2000, Dev P. Arya, currently Director of the Laboratory of Medicinal
Chemistry at Clemson University, and his coworkers discovered that neomycin inducesenormous thermal stabilization of triplex DNA while having little or almost no effect on
the B-DNA duplex stabilization.
They also showed that neomycin binds to structures that adopt A-form structure, triplexDNA being one of them. They later went on to show that neomycin even induces DNA:RNA hybrid triplex formation.
Molecular biology
Neomycin resistance is conferred by either one of two aminoglycosidephosphotransferase genes.
A neo gene is commonly included in DNAplasmids used by molecular biologists toestablish stable mammaliancell lines expressing cloned proteins in culture; manycommercially available protein expression plasmids contain neo as aselectable marker.
Non-transfectedcells will eventually die off when the culture is treated with neomycin orsimilar antibiotic. Neomycin orkanamycin can be used forprokaryotes,
butgeneticin (G418) is, in general, needed foreukaryotes.
http://en.wikipedia.org/wiki/Gram-negative_bacteriahttp://en.wikipedia.org/wiki/Gram-negative_bacteriahttp://en.wikipedia.org/wiki/Gram-positive_bacteriahttp://en.wikipedia.org/wiki/Hypersensitivityhttp://en.wikipedia.org/wiki/Polysporinhttp://en.wikipedia.org/wiki/Selman_Waksmanhttp://en.wikipedia.org/wiki/Selman_Waksmanhttp://en.wikipedia.org/wiki/Streptomyces_fradiaehttp://en.wikipedia.org/wiki/Streptomyces_fradiaehttp://en.wikipedia.org/wiki/Plasmidhttp://en.wikipedia.org/wiki/Cell_linehttp://en.wikipedia.org/wiki/Selectable_markerhttp://en.wikipedia.org/wiki/Transfecthttp://en.wikipedia.org/wiki/Kanamycinhttp://en.wikipedia.org/wiki/Prokaryoteshttp://en.wikipedia.org/wiki/Geneticinhttp://en.wikipedia.org/wiki/Eukaryoteshttp://en.wikipedia.org/wiki/Eukaryoteshttp://en.wikipedia.org/wiki/Geneticinhttp://en.wikipedia.org/wiki/Prokaryoteshttp://en.wikipedia.org/wiki/Kanamycinhttp://en.wikipedia.org/wiki/Transfecthttp://en.wikipedia.org/wiki/Selectable_markerhttp://en.wikipedia.org/wiki/Cell_linehttp://en.wikipedia.org/wiki/Plasmidhttp://en.wikipedia.org/wiki/Streptomyces_fradiaehttp://en.wikipedia.org/wiki/Selman_Waksmanhttp://en.wikipedia.org/wiki/Polysporinhttp://en.wikipedia.org/wiki/Hypersensitivityhttp://en.wikipedia.org/wiki/Gram-positive_bacteriahttp://en.wikipedia.org/wiki/Gram-negative_bacteriahttp://en.wikipedia.org/wiki/Gram-negative_bacteria8/13/2019 Amino Glyc o Sides 4444
14/25
Uses
Neomycin is overwhelmingly used as atopicalpreparation, such asNeosporin. It can also be given orally, where it is usually combined with other antibiotics. Neomycin is not absorbed from the gastrointestinal tract and has been used as a
preventive measure forhepatic encephalopathy andhypercholesterolemia.
By killing bacteria in the intestinal tract, it keeps ammonia levels low and preventshepatic encephalopathy, especially prior to GI surgery.
It has also been used to treatsmall intestinal bacterial overgrowth. It is not given intravenously, as neomycin is
extremelynephrotoxic (causeskidney damage), especially compared tootheraminoglycosides.
The exception is when neomycin is included, in very small quantities, as a preservative insome vaccines - typically 0.025 mg per dose.
KANAMYCIN
Kanamycin(also known as kanamycin A) is anaminoglycosidebactericidalantibiotic,
available inoral,intravenous, and intramuscular forms, and used to treat a wide variety
ofinfections. Kanamycin is isolated from the bacteriumStreptomyces kanamyceticus and itsmost commonly used form is kanamycinsulfate.
It is effective against some Mycoplasma and gram-positive bacteria, for instance,Staphylococcus
Pyogenes and Staphylococcus epidermidis. Along with penicillinit is found to be effective against Streptomyces fecalis. It is used invariably either alone or in combination with other drugs for a variety of
disorders, namely: acute staphylococcal infections, gonorrhea, tuberculosis, acute urinary
tract infections, for bowl sterilization in hepatic coma and also prior to bowl surgery.
Side effects
Seriousside effects include tinnitus or loss of hearing,toxicity to kidneys,andallergic reactions to thedrug
pain or irritation where the injection was given; mild skin rash; headache; fever; or nausea, vomiting.
http://en.wikipedia.org/wiki/Topicalhttp://en.wikipedia.org/wiki/Neosporinhttp://en.wikipedia.org/wiki/Neosporinhttp://en.wikipedia.org/wiki/Hepatic_encephalopathyhttp://en.wikipedia.org/wiki/Hypercholesterolemiahttp://en.wikipedia.org/wiki/Small_intestinal_bacterial_overgrowthhttp://en.wikipedia.org/wiki/Nephrotoxichttp://en.wikipedia.org/wiki/Kidneyhttp://en.wikipedia.org/wiki/Aminoglycosidehttp://en.wikipedia.org/wiki/Aminoglycosidehttp://en.wikipedia.org/wiki/Bacteriocidalhttp://en.wikipedia.org/wiki/Antibiotichttp://en.wiktionary.org/wiki/oralhttp://en.wikipedia.org/wiki/Intravenoushttp://en.wikipedia.org/wiki/Infectionhttp://en.wikipedia.org/wiki/Streptomyces_kanamyceticushttp://en.wikipedia.org/wiki/Sulfatehttp://en.wikipedia.org/wiki/Adverse_effect_(medicine)http://en.wikipedia.org/wiki/Toxicity_to_kidneyshttp://en.wikipedia.org/wiki/Allergichttp://en.wikipedia.org/wiki/Medicationhttp://en.wikipedia.org/wiki/Medicationhttp://en.wikipedia.org/wiki/Medicationhttp://en.wikipedia.org/wiki/Allergichttp://en.wikipedia.org/wiki/Toxicity_to_kidneyshttp://en.wikipedia.org/wiki/Adverse_effect_(medicine)http://en.wikipedia.org/wiki/Sulfatehttp://en.wikipedia.org/wiki/Streptomyces_kanamyceticushttp://en.wikipedia.org/wiki/Infectionhttp://en.wikipedia.org/wiki/Intravenoushttp://en.wiktionary.org/wiki/oralhttp://en.wikipedia.org/wiki/Antibiotichttp://en.wikipedia.org/wiki/Bacteriocidalhttp://en.wikipedia.org/wiki/Aminoglycosidehttp://en.wikipedia.org/wiki/Aminoglycosidehttp://en.wikipedia.org/wiki/Kidneyhttp://en.wikipedia.org/wiki/Nephrotoxichttp://en.wikipedia.org/wiki/Small_intestinal_bacterial_overgrowthhttp://en.wikipedia.org/wiki/Hypercholesterolemiahttp://en.wikipedia.org/wiki/Hepatic_encephalopathyhttp://en.wikipedia.org/wiki/Neosporinhttp://en.wikipedia.org/wiki/Topical8/13/2019 Amino Glyc o Sides 4444
15/25
Kanamycin INN, Kanamycin Sulphate BAN, Kanamycin Sulfate USAN,
8/13/2019 Amino Glyc o Sides 4444
16/25
KANAMYCIN
2-(aminomethyl) - 6-[4,6-diamino-3- [4-amino-3,5-dihydroxy-6-(hydroxymethyl)
tetrahydropyran-2-yl]oxy- 2-hydroxy- cyclohexoxy]- tetrahydropyran- 3,4,5-triol
In US the use of kanamycin is normally restricted to the infections related to theintestinal tract, such as: bacillary dysentry; systemic infections caused due to Gram-negative bacili, such as Klebsiella, Proteus, Enterobacter, and Serratia spp., which have
developed resistance to some other antibiotics. It has also been indicated for preoperative
antisepsis of the bowel. However, this drug could not be useful in tuberculosi s perhapsdue to the fact that it develops resistance to mycoorganism rather rapidly.
Dose :
(Base equivalent)-Oral, adult, for intestinal infection, 1g after every 8 hours for 5 to 7days ; For preparative preparations, 1g every hour for 4 doses followed by 1g every 6
hours for 36 to 72 hours.
Mechanism of Action.
Based on both clinical experience and experimental demonstration it has been dulyobserved that the drug develops cross-resistance overwhelmingly in the tubercle bacilli
specifically along with some other medicinal entities, such as: vincomycin,
dihydrostreptomycin and antitubercular drug substances.
SAR of Kanamycin.
Kanamycins A, B and C i.e., the three closely related analogues of kanamycin have beenduly established by the aid of chromatography.
Kanamycin A is the drug available for therapeutic usage.
8/13/2019 Amino Glyc o Sides 4444
17/25
It has been proved that the vital point of difference amongst the kanamycins residessolely in the sugar residuces strategically linked to the glycosidic oxygen at the C-4
position of the central deoxystreptamine.
Interestingly, the kanamycins do not essentially possess the D-ribose residue as ispresent in neomycins and paromomycins. In all the three structural variants of kanamycinthe presence of kanosamine entity is found to be attached glycosidically at the C-6
position of deoxystreptamine i.e., 3-D-glucosamine.
They also differ in the substituted D-glucoses which are observed to be attachedglycosidically at the C-4 position of the inherent deoxystreptamine ring.
Uses in research
Kanamycin is used in molecular biology as a selective agent most commonly toisolatebacteria (e.g.,E. coli)which have taken up genes (e.g., ofplasmids)coupled to a
gene coding for kanamycin resistance (primarily Neomycin phosphotransferase II [NPT
II/Neo]).
Bacteria that have beentransformed with a plasmid containing the kanamycin resistancegene are plated on kanamycin (50-100 ug/ml) containingagarplates or are grown in
media containing kanamycin (50-100 ug/ml).
Only the bacteria that have successfully taken up the kanamycin resistance gene becomeresistant and will grow under these conditions.
As a powder kanamycin is white to off-white and is soluble in water (50 mg/ml). Mammalian cells and othereukaryotes are screened usingG418, a similar
aminoglycoside antibiotic, which KanMX confers resistance against. At least one such gene,Atwbc19is native to a plant species, of comparatively large size
and its coded protein acts in a manner which decreases the possibility of transfer from the
plant to bacteria; it may be incapable of giving resistance to bacteria even if gene transfer
occurs.
GENTAMICIN
Inexpensive and reliable efficacy. Usual dose; 3-5 mg per Kg body wt in 3 divided doses daily. Therapeutic Applications: UTI, Pneumonia (nosocomial), Peritonitis, meningitis and
sepsis.
http://en.wikipedia.org/wiki/Bacteriahttp://en.wikipedia.org/wiki/E._colihttp://en.wikipedia.org/wiki/Plasmidhttp://en.wikipedia.org/wiki/Transformation_(genetics)http://en.wikipedia.org/wiki/Agarhttp://en.wikipedia.org/wiki/Eukaryotehttp://en.wikipedia.org/wiki/Geneticinhttp://en.wikipedia.org/wiki/Geneticinhttp://en.wikipedia.org/wiki/Eukaryotehttp://en.wikipedia.org/wiki/Agarhttp://en.wikipedia.org/wiki/Transformation_(genetics)http://en.wikipedia.org/wiki/Plasmidhttp://en.wikipedia.org/wiki/E._colihttp://en.wikipedia.org/wiki/Bacteria8/13/2019 Amino Glyc o Sides 4444
18/25
TETRACYCLINES
Broad spectrum antibiotics (incl: Legionella spp, Ureaplasma, Mycoplasma, chlamydiaplasmodium and rickettsial infections)
Origin: Streptomyces spp Examples: Chlortetracycline, demeclocyline, oxytetracycline, doxycline, tetracycline,
minocycline
Mechanism of action:
Binding of the 30S subunit of ribosome, preventing the access of aminoacyltRNA to theacceptor site on the mRNA-ribosome complex
Resistance
Plasmid mediated decrease accumulation of the drug
Blockade of access by ribosome protecting protein Enzymatic inactivation of TCN
Absorption, Distribution and Elimination
Most are incompletely absorbed when taken orally* Abs occurs mainly in the stomach and upper small intestine Fasting improves abs while presence of food or divalent cations reduce Peak conc ~ 2-4 hr T1/2: 6-12 hrs+ Undergoes entero-hepatic cycling Most tetracyclines are excreted in urine (doxicycline, an exception) Clinical uses Wide range of bacteria diseases
Ricketsial infections Mycoplasma Chlamydia
Unwanted effects
GI upset including abd pain, nausea, vomiting diarrhea Photosensitivity Hepatotoxicity Renal toxicity Teeth and bone discolouration Skin rashes Pseudomembranous colitis
8/13/2019 Amino Glyc o Sides 4444
19/25
Thrombophlebitis (IV) Pseudo-tumourcerebri Leukopenia, Thrombocytopenic purpura
CHLORAMPHENICOL
Broad spectrum antibiotic (MIC for sensitive strains < 8 ug/ml) Antimicrobial spectrum: Rickettsial,salmonella infections
Mechanism
Inhibition of protein synthesis via 50S subunit of ribosomeResistance
Plasmid mediated elaboration of inactivating enzymes (acetyl transferase) Introduced to clinical practice in 1949 Bacteriostatic Fallen out favour in western countries cos it causes aplastic anaemia Main use restricted as eye ointment/drops Poorly dissolves in water requiring that IV is given as succinate ester. The succinate ester is incompletely hydrolysed (70%); Usual oral dose = 50 mg per kg IV usually 75 mg per kg Drug level to be monitored in neonates to < 4 yrs old, elderly, renal impaired patients Recommended peak level 15-25 mg/ml (sample taken 1 hr after dose) Trough level < 15mg/kg (sample taken b4 next dose)
Absorption, Distribution and Elimination
Well absorbed when given orally, (IM not advised as it is poorly absorbed) Peak conc achieved within 2 hours
60% of plasma found in CSF T1/2 2 hours 10% unchanged in urine, the rest is inactivated by glucuronidation in the liver
ADRs
Gray baby syndrome (consisting of: VDFlaccidityHypothermia Ashen-gray colour); Graysyndrome
8/13/2019 Amino Glyc o Sides 4444
20/25
Jarisch_Hexheimer reactions when used in brucellosis Bone marrow suppression:
o presents with low Hb;o does not predict Aplastic anaemia,o dose dependent (>20g)
Risk of leukaemia
Bone marrow aplasia* Not dose dependent Unpredictable commonest with oral (1:24000, least with eye preps (1: ~250000); may begin weeks after stopping drug
Interactions: Phenytoin, phenobarb, Rifampicin, chlorpropamide, dicoumarol
QUINOLONES
Group of broad spectrum antibiotics Also known as DNA gyrase Generally bactericidal May be broadly divided into two groups
Fluoroquinolones Other quinolones: Nalidixic acid, the oldest member, cinoxacin
Mechanism
Penetrates bacterial cell easily Inhibition of DNA gyrase(in eukaroytes is called Topoisomerase II)
Prevents DNA replication Blocks transcription Resistance results from:Increased efflux of drug
Altered DNA gyrase binding site
8/13/2019 Amino Glyc o Sides 4444
21/25
Classes of quinolones
4 generations (plus!) Earlier generations have narrower spectrum 1stgeneration: Nalidixic acid, cinoxacin, oxolinic acid 2ndgeneration: ciprofoxacin, enoxacin, ofloxacin, norfloxacin 3rd: sparfloxacin, levofloxacin 4th: gatifloxacin, sitafloxacin
Absorption, Distribution and Elimination
General good absorption profile Achieves peak plasma conc. 1-3 hrs Food may reduce rate but not extent of absorption Bioavailability ranges from 50-90% Kidneys involved in excretion
Clinical uses
UTI Travellers diarrhoea Bone, joint soft tissues infections Respiratory infections ESP.
o Legionella sppo Mycoplasma
Mycobacterium spp infections Other organisms: Chlamydia, Brucella
ADRs
Peripheral neuropathy Tendonitis and tendon rupture can occur
Rhabdomyolysis SJS Pseudomembranous colitis Prolongation of QT interval Not recommended in pre-pubertal bcos of tendency to cause arthropathy
8/13/2019 Amino Glyc o Sides 4444
22/25
MACROLIDES
Many membered lactone ring plus deoxy sugar Bacteriostatic antibiotics Inhibits protein synthesis (50S) Resistance is usually plasmid mediated reduced
o Erythromycino Azithromycino Clarithromycin
Spectrum of antibacterial activity Mostly Gram +ve Diphtheria Mycoplasma Legionella Mycobacteria
Borelli Erythromycin base is susceptible to gastric acid inactivation Thus, it is usually presented in enteric form Poorly penetrates CNS but crosses placenta barrier Plasma protein binding 70-90% Half-life is ~ 2 hours Clinical uses include: Toxoplasmosis and cryptosporidiosis in HIV/AIDS
o Chlamydia, mycoplasma, pertusis, tetanus, syphilis, H. pyloriARBEKACIN
Arbekacin(INN)is a semisyntheticaminoglycosideantibiotic. It is primarily used for the treatment of infections caused by multi-resistant bacteria
includingmethicillin-resistant Staphylococcus aureus (MRSA).
Arbekacin was originally synthesized fromdibekacin in 1973. It has been registered and marketed in Japan since 1990 under the trade name Habekacin. Arbekacin is no longer covered by patent and generic versions of the drug are also
available under such trade names as Decontasin and Blubatosine.
Mechanism of action
Aminoglycosides, such as 'Arbekacin, inhibit protein synthesis in susceptible bacteria byirreversibly binding to bacterial 30S and 16S ribosomal subunits.
Specifically Arbekacin binds to four nucleotides of 16S rRNA and a single amino acid ofprotein S12.
This interferes with decoding site in the vicinity of nucleotide 1400 in 16S rRNA of 30Ssubunit.
This region interacts with the wobble base in the anticodon of tRNA.
http://en.wikipedia.org/wiki/International_Nonproprietary_Namehttp://en.wikipedia.org/wiki/Aminoglycosidehttp://en.wikipedia.org/wiki/Antibiotichttp://en.wikipedia.org/wiki/Methicillin-resistant_Staphylococcus_aureushttp://en.wikipedia.org/wiki/Dibekacinhttp://en.wikipedia.org/wiki/Dibekacinhttp://en.wikipedia.org/wiki/Methicillin-resistant_Staphylococcus_aureushttp://en.wikipedia.org/wiki/Antibiotichttp://en.wikipedia.org/wiki/Aminoglycosidehttp://en.wikipedia.org/wiki/International_Nonproprietary_Name8/13/2019 Amino Glyc o Sides 4444
23/25
This leads to misreading of mRNA so incorrect amino acids are inserted into thepolypeptide leading to nonfunctional or toxic peptides and the breakup of polysomes into
nonfunctionalmonosomes.
Toxicity
Ototoxicity and nephrotoxicity are the most serious adverse effects of aminoglycosidetherapy and are more likely to occur in patients with a history of renal impairment or who
are receiving other ototoxic and/or nephrotoxic drugs.
Normal duration of IM or IV aminoglycoside therapy is 7-10 days Although a longer duration may be necessary in some cases, toxicity is more likely to
occur when aminoglycoside treatment is continued for longer than 10 days.
PAROMOMYCIN
Paromomycinis anaminoglycoside antibiotic, first isolated from Streptomyces
krestomuceticus in the 1950s. It was discovered byParke Davis nowPfizer and introduced
asHumatin in 1960.It is also called monomycinand aminosidine;
Mechanism
Paromomycin is aprotein synthesis inhibitor in non-resistant cells by bindingto16Sribosomal RNA.This broad spectrum antibiotic soluble in water, is very similar in
action to Neomycin.
Antimicrobial activity of Paromomycin againstEscherichia coli andStaphylococcusaureus has been shown.
PAROMOMYCIN
6-diamino-2-[(2S, 3R, 4R, 5R)-4-[(2R, 3R, 4R, 5R, 6S)-3-amino-6-(amino methyl)-4
http://en.wikipedia.org/wiki/Aminoglycosidehttp://en.wikipedia.org/wiki/Parke_Davishttp://en.wikipedia.org/wiki/Pfizerhttp://en.wikipedia.org/wiki/Protein_synthesis_inhibitorhttp://en.wikipedia.org/wiki/16S_ribosomal_RNAhttp://en.wikipedia.org/wiki/Ribosomal_RNAhttp://en.wikipedia.org/wiki/Escherichia_colihttp://en.wikipedia.org/wiki/Staphylococcus_aureushttp://en.wikipedia.org/wiki/Staphylococcus_aureushttp://en.wikipedia.org/wiki/Staphylococcus_aureushttp://en.wikipedia.org/wiki/Staphylococcus_aureushttp://en.wikipedia.org/wiki/Escherichia_colihttp://en.wikipedia.org/wiki/Ribosomal_RNAhttp://en.wikipedia.org/wiki/16S_ribosomal_RNAhttp://en.wikipedia.org/wiki/Protein_synthesis_inhibitorhttp://en.wikipedia.org/wiki/Pfizerhttp://en.wikipedia.org/wiki/Parke_Davishttp://en.wikipedia.org/wiki/Aminoglycoside8/13/2019 Amino Glyc o Sides 4444
24/25
Uses
It is an antibiotic used to treat intestinal infections suchascryptosporidiosis andamoebiasis,and other diseases likeleishmaniasis.
Paromomycin was demonstrated to be effective againstcutaneous leishmaniasis inclinical studies in theUSSR in the 1960s, and in trials withvisceral leishmaniasis in the
early 1990s.
The route of administration isintramuscular injection andcapsule.Paromomycin topical cream with or without gentamicin is an effective treatment for
ulcerative cutaneous leishmaniasis, according to the results of a phase 3, randomized,
double-blind, parallel groupcontrolled trial.
http://en.wikipedia.org/wiki/Cryptosporidiosishttp://en.wikipedia.org/wiki/Amoebiasishttp://en.wikipedia.org/wiki/Leishmaniasishttp://en.wikipedia.org/wiki/Cutaneous_leishmaniasishttp://en.wikipedia.org/wiki/USSRhttp://en.wikipedia.org/wiki/Visceral_leishmaniasishttp://en.wikipedia.org/wiki/Intramuscular_injectionhttp://en.wikipedia.org/wiki/Capsule_(pharmacy)http://en.wikipedia.org/wiki/Capsule_(pharmacy)http://en.wikipedia.org/wiki/Intramuscular_injectionhttp://en.wikipedia.org/wiki/Visceral_leishmaniasishttp://en.wikipedia.org/wiki/USSRhttp://en.wikipedia.org/wiki/Cutaneous_leishmaniasishttp://en.wikipedia.org/wiki/Leishmaniasishttp://en.wikipedia.org/wiki/Amoebiasishttp://en.wikipedia.org/wiki/Cryptosporidiosis8/13/2019 Amino Glyc o Sides 4444
25/25
REFERENCES
1. Aminoglycosides at the US National Library of Medicine Medical Subject Headings (MeSH)
2. "Bacterial 'battle for survival' leads to new antibiotic" (Press release). Massachusetts Institute
of Technology. February 26, 2008. Retrieved December 1, 2010.
3. Ryden, R; Moore (1977). "BJ".J Antimicrob Chemother3(6): 609
613. doi:10.1093/jac/3.6.609 PMID 340441
4. Kroppenstedt RM, Mayilraj S, Wink JM (Jun 2005). "Eight new species of the genus
Micromonospora, Micromonospora citrea sp. nov., Micromonospora echinaurantiaca sp. nov.,
Micromonospora echinofusca sp. nov. Micromonospora fulviviridis sp. nov., Micromonosporainyonensis sp. nov., Micromonospora peucetia sp. nov., Micromonospora sagamiensis sp. nov.,
and Micromonospora viridifaciens sp. nov". Syst Appl Microbiol.28(4): 328
39. doi:10.1016/j.syapm.2004.12.011. PMID 15997706
5. Paul M. Dewick (2009).Medicinal Natural Products: A Biosynthetic Approach (3rd ed.).
While. ISBN 0-470-74167-8
6. Falagas, Matthew E; Grammatikos, Alexandros P; Michalopoulos, Argyris (2008). "Potential
of old-generation antibiotics to address current need for new antibiotics". Expert Review of Anti-
infective Therapy6(5): 593600.doi:10.1586/14787210.6.5.593. PMID 18847400
7.Durante- Mangoni, Emanuele; Grammatikos, Alexandros; Utili, Riccardo; Falagas, Matthew
E. (2009). "Do we still need the aminoglycosides?.International Journal of Antimicrobial
Agents33(3): 2015.doi:10.1016/j.ijantimicag.2008.09.001. PMID 18976888
8. Merck Manual > Bacteria and Antibacterial Drugs Last full review/revision July 2009 by
Matthew E. Levison, MD
9. Gautam Mehta and Bilal Iqbal. Clinical Medicine for the MRCP PACES. Volume 1. Core
Clinical Skills. Oxford University Press. 2010.